Response to therapy in a patient with coexisting Langerhans cell histiocytosis (LCH) and neuroblastoma emphasizes the need for the addition of LCH-directed therapy

被引：0
|
作者：
Grant, RM [1 ]
Capra, M [1 ]
Gerstle, T [1 ]
Weitzman, S [1 ]
机构：
[1] Hosp Sick Children, Toronto, ON M5G 1X8, Canada
来源：
PEDIATRIC BLOOD & CANCER | 2004年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 37 条
  • [21] PCR-Based Detection of Langerhans Cell Histiocytosis (LCH) Molecular Signal in Cell-Free DNA from Patient Cerebrospinal Fluids (CSF)
    Shang, Sam
    McIntyre, John
    Anderson, Ronald
    Narendran, Aru
    Greenway, Steven
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
  • [22] Response to subcutaneous therapy with mistletoe in recurrent multisystem Langerhans cell histiocytosis
    Seifert, Georg
    Laengler, Alfred
    Tautz, Christoph
    Seeger, Karl
    Henze, Guenter
    PEDIATRIC BLOOD & CANCER, 2007, 48 (05) : 591 - 592
  • [23] Effective Second Line Treatment with Cytarabine in a Patient with Refractory Multisystem Langerhans Cell Histiocytosis (LCH) Complicated with Macrophage Activation Syndrome (HLH-MAS)
    Petrikkos, Loizos
    Papadakis, Vassilios
    Nikas, Ioannis
    Tsitsikas, Kostantinos
    Stefanaki, Kalliopi
    Valari, Manthoula
    Polychronopoulou, Sophia
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S30 - S31
  • [24] Radiologic zebra line sign in a patient with Langerhans cell histiocytosis on bisphosphonate therapy
    Sakamoto, Kenichi
    Shioda, Yoko
    EJHAEM, 2022, 3 (03): : 1046 - 1047
  • [25] EARLY MORTALITY IN LANGERHANS CELL HISTIOCYTOSIS III (LCH-III) TRIAL SUGGESTS SOME PATIENTS REQUIRE MORE EFFECTIVE THERAPY EVEN BEFORE THE 1ST RESPONSE ASSESSMENT POINT AT 6 WEEKS
    Visser, Johannes
    Potschger, Ulrike
    Thiem, Elfriede
    Minkov, Milen
    Arico, Maurizio
    Astigarraga, Itziar
    Braier, Jorge
    Donadieu, Jean
    Grois, Nicole
    Gadner, Helmut
    Henter, Jan-Inge
    Janka-Schaub, Gritta
    McClain, Kenneth
    Weitzman, Sheila
    Windebank, Kevin
    Ladisch, Stephan
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S16 - S16
  • [26] Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis
    Kolde, G
    Schulze, P
    Sterry, W
    ACTA DERMATO-VENEREOLOGICA, 2002, 82 (05) : 384 - 386
  • [27] Langerhans cell histiocytosis in pediatric patient responsive to vemurafenib after refractory to initial therapy and significant morbidity to salvage therapy
    Mohr, Kayla
    Gardner, Jerad
    Kincannon, Jay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB231 - AB231
  • [28] Group I Therapy Dependence in a Patient with Marijuana-Induced Pulmonary Langerhans Cell Histiocytosis
    Fuerst, N. H.
    Bernens, M. D.
    Eggert, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [29] Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS database
    Touraine, Philippe
    Sagna, Yempabou
    Mattsson, Anders F.
    Burman, Pia
    Van Beek, Andre P.
    Carlsson, Martin Ove
    Aydin, Ferah
    Feldt-Rasmussen, Ulla
    Camacho-Hubner, Cecilia
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 187 (03) : 373 - 381
  • [30] Positive and negative effects of biphosphonate therapy in an adult patient with Langerhans' cell histiocytosis and multiple bone lesions
    Fichter, J.
    Muller-Reichert, H.
    Doberauer, C.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (07) : 757 - 757
1234